Researchers at Weill Cornell Medicine and Birkbeck, University of London, have identified a site where a commonly used ...
A new review was published in Volume 13 of Oncoscience on May 22, 2026, titled "Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression." ...
UCLA researchers found NDRG1 builds up in old muscle stem cells, slowing repair but boosting survival. Blocking it speeds ...
The high-grade glioma market is witnessing steady growth driven by the rising incidence of aggressive brain tumors, increasing awareness, and advancements ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...
BDRX READ THE FULL BDRX RESEARCH REPORT Business Update Expanding Phase 3 Serenta Trial into Canada On June 29, 2026, Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) announced that Health Canada gave ...
A new review was published in Volume 18 of Aging on May 30, 2026, titled "The love and hate relationship between cellular ...
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted ...
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules ...
Palvella Therapeutics Inc (NASDAQ:PVLA) shares gained 5% in premarket trading on Monday after the company announced that the U. S.
Nutrient surplus sensing through PI3K (phosphoinositide-3-kinase) and mTOR (mechanistic target of rapamycin) stimulates anabolism to expand cellular mass, whereas nutrient and energy deprivation ...
Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results